Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Segelov

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experienceE Segelov, J Campbell, M Ng, et al.
British Journal of Cancer|July 30, 2014
The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trialsE Segelov, D Chan, J Shapiro, et al.
Journal of Medical Genetics|July 5, 2003
Alterations of the Birt-Hogg-Dubé gene (BHD) in sporadic colorectal tumoursK Kahnoski, S K Khoo, N T Nassif, et al.
Current Oncology (Toronto, Ont.)|November 11, 2020
Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemicS Bennett, K Søreide, S Gholami, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 3, 2019
Supportive oncofertility care, psychological health and reproductive concerns: a qualitative studyY Wang, Shanna Logan, K Stern, et al.
Oncogene|October 13, 2015
JRK is a positive regulator of β-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancerL Pangon, I Ng, M Giry-Laterriere, et al.
Asia-Pacific Journal of Clinical Oncology|October 2, 2018
The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailableL Chin-Lenn, R H De Boer, E Segelov, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experienceE Segelov, J Campbell, M Ng, et al.
British Journal of Cancer|July 30, 2014
The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trialsE Segelov, D Chan, J Shapiro, et al.
Journal of Medical Genetics|July 5, 2003
Alterations of the Birt-Hogg-Dubé gene (BHD) in sporadic colorectal tumoursK Kahnoski, S K Khoo, N T Nassif, et al.
Current Oncology (Toronto, Ont.)|November 11, 2020
Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemicS Bennett, K Søreide, S Gholami, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 3, 2019
Supportive oncofertility care, psychological health and reproductive concerns: a qualitative studyY Wang, Shanna Logan, K Stern, et al.
Oncogene|October 13, 2015
JRK is a positive regulator of β-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancerL Pangon, I Ng, M Giry-Laterriere, et al.
Asia-Pacific Journal of Clinical Oncology|October 2, 2018
The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailableL Chin-Lenn, R H De Boer, E Segelov, et al.
Pageof 2